Corvus Pharmaceuticals
CRVS
52 hedge funds and large institutions have $28M invested in Corvus Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 11 reducing their positions, and 10 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 11
1% more call options, than puts
Call options by funds: $114K | Put options by funds: $113K
0% more funds holding
Funds holding: 52 → 52 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
2.68% less ownership
Funds ownership: 41.86% → 39.18% (-2.7%)
37% less capital invested
Capital invested by funds: $44.6M → $28M (-$16.6M)
Top Buyers
| 1 |
SC
Samlyn Capital
New York
|
+$634K |
| 2 |
TL
TowerView LLC
New York
|
+$291K |
| 3 |
Millennium Management
New York
|
+$228K |
| 4 |
Two Sigma Advisers
New York
|
+$148K |
| 5 |
JP Morgan Chase
New York
|
+$145K |
Top Sellers
| 1 |
AG
Artal Group
Luxembourg
|
-$1.15M |
| 2 |
CA
CHI Advisors
New York
|
-$458K |
| 3 |
CIC
Cornercap Investment Counsel
Atlanta,
Georgia
|
-$223K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$213K |
| 5 |
Renaissance Technologies
New York
|
-$144K |
CRVS Hedge Fund Activity: Q3 2023 in Review
52 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q3 2023, worth a combined $28M — down 37% from $44.6M a quarter earlier.
Fund positioning in CRVS was balanced in Q3 2023: 10 funds opened new positions, 10 closed out, 15 added to existing stakes and 11 trimmed.
The largest buyer was Samlyn Capital, adding an estimated $634K. The largest seller was Artal Group, exiting entirely with an estimated $1.15M sold.
- 52 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $28M of Corvus Pharmaceuticals stock for Q3 2023, down 37% quarter-over-quarter.
- 10 funds opened new Corvus Pharmaceuticals positions in Q3 2023 and 10 closed out, a net change of 0 holders.
- The largest Corvus Pharmaceuticals buyer in Q3 2023 was Samlyn Capital, an estimated $634K added.
- The largest Corvus Pharmaceuticals seller in Q3 2023 was Artal Group, an estimated $1.15M sold.
Based on aggregated 13F filings for Q3 2023.